This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
If the current rates of growth of the senior population and prevalence of Alzheimer disease (AD) continue, the number of individuals worldwide affected by this disabling disease will double from 24.3 to 42.3 million by 2020.1 Given the devastating impact of AD on patient, family, community, and society, considerable efforts are underway to unravel its pathophysiologic mechanisms, with the aim of developing safe and effective disease-modifying therapies. Such therapies will probably be most efficacious in the early symptomatic or ideally pre-symptomatic stages of the disease.2 An accurate diagnosis of AD in the early symptomatic stage is extremely challenging despite the development of useful clinical constructs like mild cognitive impairment (MCI), which enables the identification of individuals who may be in an early clinical phase of AD. Future diagnostic approaches toward early symptomatic and presymptomatic AD will almost certainly hinge upon biomarkers. In fact, new diagnostic criteria were recently proposed that operationalize the pre-dementia diagnosis of AD and include imaging and CSF biomarkers as supportive evidence.3 Beyond their use in diagnostics, imaging and other biomarkers will likely serve important roles in monitoring effects of …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
